Public-registry trials using IBI314 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 | Innovent Biologics (Suzhou) Co. Ltd. | COVID-19 | PHASE1 / PHASE2 | 19 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →